Clinical Research Directory
Browse clinical research sites, groups, and studies.
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
Sponsor: Merck Sharp & Dohme LLC
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
Official title: A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis
Key Details
Gender
All
Age Range
65 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2022-07-01
Completion Date
2023-01-10
Last Updated
2026-04-29
Healthy Volunteers
No
Conditions
Interventions
Elpipodect
MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
Placebo
MK-8189 matching placebo administered orally QD
Locations (8)
CITrials ( Site 0007)
Santa Ana, California, United States
Top Medical Research ( Site 0005)
Cutler Bay, Florida, United States
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida, United States
Well Pharma Medical Research, Corp. ( Site 0006)
Miami, Florida, United States
Atlanta Center for Medical Research ( Site 0004)
Atlanta, Georgia, United States
iResearch Atlanta ( Site 0009)
Decatur, Georgia, United States
Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008)
Princeton, New Jersey, United States
Richmond Behavioral Associates ( Site 0003)
Staten Island, New York, United States